CDKN2A and glioblastoma: Furthermore, Hsu et al. [28] demonstrated that patients with CDKN2A deletions and NF1 mutations exhibited poorer overall survival rates, whereas patients with CDKN2A wild-type status showed improved overall survival in glioblastoma cases.